Table 2.
Markers suggestive of ongoing hemolysis and hematopoietic recovery for the trial participants at various timepoints after OTQ923 infusion
| Participant 1 | Participant 2 | Participant 3 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal Range | Screening | Month 3 | Month 6 | Month 12 | Month 18 | Screening | Month 3 | Month 6 | Month 12 | Screening | Month 3 | Month 6 | |
| Absolute Reticulocytes (106/mm3) | 0.021–0.085 | 0.3364 | 0.4025 | 0.2419 | 0.2721 | 0.1943 | 0.3034 | 0.3478 | 0.3951 | 0.3802 | 0.3444 | 0.1841 | 0.2321 |
| Lactate dehydrogenase (LDH)(U/L) | 94–260 | 345 | 265 | 263 | 217 | 292 * | 397 | 387 | 284 | 243 | 359 | 341 | 325 |
| Total bilirubin (μmol/L) | 3–21 | 26 | 24 | 48 | 43 | 56 * | 60 | 32 | 65 | 72 | 67 | 31 | 31 |
Abnormal values are bolded.
*
These laboratory studies were collected a few weeks after the patient had a motor vehicle accident and sustained a liver laceration. Hence their significance needs to be interpreted in conjunction with the patient’s clinical status.